Clinical trials for Lung cancer

281 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 2 Lung cancer #NCT06868485 #2024-519713-65-00

Étude visant à évaluer l'efficacité du WSD0922-FU chez les patients atteints d'un cancer du poumon non à petites cellules avancé C797S +

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy

Systemic Treatment-Naive

5 recruiting sites

Wayshine Biopharm, Inc.

Phase 2 Lung cancer #NCT05498428 #2023-505065-91-00

[PALOMA-2] Étude de l'AMIVANTAMAB chez des patients atteints d'un cancer du poumon non à petites cellules muté EGFR - Cohorte 4

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic 1 Bispecific T-cell engager antibodies

5 recruiting sites

Janssen

Phase 2 Lung cancer #NCT05609578 #2023-503714-77-00

Essai de phase 2 sur les thérapies combinées avec l'ADAGRASIB chez des patients atteints d'un cancer du poumon non à petites cellules avancé avec mutation KRAS G12C - Cohorte C

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Immunotherapy Chemotherapy

Targeted therapy Targeted therapy

8 recruiting sites

Mirati Thérapeutique Inc.

Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05503797 #2024-513578-23-00

Etude visant à évaluer l'efficacité et la sécurité du FORE8394 chez des participants atteints d'un cancer présentant des altérations du gène BRAF - Sous protocole A

Locally Advanced Metastatic BRAF 1 2 3 or more

KRAS G12C KRAS non G12C NRAS HRAS Systemic Treatment-Naive

7 recruiting sites

Fore Biotherapeutics

Phase 2 Lung cancer #NCT05865730 #2024-516711-24-00

Étude d'Oncobax®-AK chez des patients atteints de tumeurs solides avancées

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Metastatic PDL1 Positive (>= 50%)

2 recruiting sites

EverImmune

Phase 2 Lung cancer #NCT05498428 #2023-505065-91-00

[PALOMA-2] Étude de l'AMIVANTAMAB chez des patients atteints d'un cancer du poumon non à petites cellules muté EGFR - Cohortes 1, 5 et 6

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive

5 recruiting sites

Janssen

Phase 2 Lung cancer #NCT06667908

[CONVERGE] Étude du JNJ-90301900 en association avec une chimioradiothérapie suivie d'une immunothérapie de consolidation pour le cancer du poumon non à petites cellules

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced None Systemic Treatment-Naive

5 recruiting sites

Janssen

Phase 2 Lung cancer #NCT05718323

[RAISE] Essai évaluant l'ajout du NIRAPARIB au traitement d'entretien par anticorps anti-PD-L1 chez les patients atteints d'un cancer bronchique à petites cellules métastatique SLFN11-positifs

SCLC (Small Cell Lung Cancer) Metastatic None Immunotherapy Chemotherapy

Systemic Treatment-Naive

3 recruiting sites

ETOP IBCSG Partners Foundation

Phase 2 Lung cancer #NCT05742607

[MATISSE] IPH5201 et DURVALUMAB chez les patients atteints d'un cancer du poumon non à petites cellules résécable

NSCLC (Non-Small Cell Lung Cancer) Localized None Systemic Treatment-Naive

ALK EGFR Immunotherapy Targeted therapy

6 recruiting sites

Innate Pharma

Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06898450

Une étude visant à évaluer la sécurité, la tolérance et l'efficacité du NDI-219216 chez les patients atteints de tumeurs solides avancées.

Parties A and B (Patients non sélectionnés)

Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more

Systemic Treatment-Naive

2 recruiting sites

Nimbus Wadjet, Inc.